About Complement component 1 Q subcomponent-binding protein, mitochondrial
Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) is a protein
from Homo sapiens identified by UniProt accession
Q07021, 282 residues long.
MolForge cross-references it against 0 known binders and
182 disease associations.
Target properties
| Protein name | Complement component 1 Q subcomponent-binding protein, mitochondrial |
| UniProt accession | Q07021 |
| Gene | C1QBP |
| Organism | Homo sapiens |
| Length | 282 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (182)
Diseases linked to this target (Open Targets).
- combined oxidative phosphorylation deficiency 33 · score 0.74
- Mitochondrial disorder due to a defect in mitochondrial protein synthesis · score 0.55
- neurodegenerative disease · score 0.46
- cardiomyopathy · score 0.37
- mitochondrial disease · score 0.37
- myopathy · score 0.37
- metabolic acidosis · score 0.37
- Metabolic acidosis · score 0.37
- Myopathy · score 0.37
- squamous cell lung carcinoma · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q07021-F1 | alphafold | PREDICTED | 75.07 | — |
Amino-acid sequence (282 residues)
MLPLLRCVPR VLGSSVAGLR AAAPASPFRQ LLQPAPRLCT RPFGLLSVRA GSERRPGLLR PRGPCACGCG CGSLHTDGDK AFVDFLSDEI KEERKIQKHK TLPKMSGGWE LELNGTEAKL VRKVAGEKIT VTFNINNSIP PTFDGEEEPS QGQKVEEQEP ELTSTPNFVV EVIKNDDGKK ALVLDCHYPE DEVGQEDEAE SDIFSIREVS FQSTGESEWK DTNYTLNTDS LDWALYDHLM DFLADRGVDN TFADELVELS TALEHQEYIT FLEDLKSFVK SQ
Explore Complement component 1 Q subcomponent-binding protein, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets